LHFPL7 and colonic neoplasm: Our results showed that colon cancer patients with high TMEM211 expression had poor progression-free interval survival [PFIS, adjusted hazard ratio [33]: 1.91, 95% CI: 1.11–3.27, p = 0.019, Table 3] and disease-specific survival (DSS, AHR: 2.30, 95% CI: 1.15–4.60, p = 0.019, Table 3).